Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

39.15 -0.25 (-0.63%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,111,729
Open 39.27
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 39.40
Today's Range 38.97 - 39.29
52wk Range 27.95 - 43.32
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control
Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e 
Via Benzinga
New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)
From Genentech
Via Business Wire

Performance

YTD
-0.31%
-0.31%
1 Month
-1.01%
-1.01%
3 Month
+9.51%
+9.51%
6 Month
-3.36%
-3.36%
1 Year
-2.73%
-2.73%

More News

Read More
Why Shares of Zentalis Pharmaceuticals Dropped This Week
Via The Motley Fool
Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class
Via Investor's Business Daily
Stock Analysis: Roche Holding AG
Via Talk Markets
Why Shares of Rain Oncology Are Plummeting Today
Via The Motley Fool
Apple Thwarts $2B In Fraud Transactions, UBS Takes $17B Hit From 'Hasty Credit Suisse Takeover,' Verizon Streamlines Unlimited Data Plans: Today's Top Stories
Via Benzinga
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
Via Benzinga
Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis
From Genentech
Via Business Wire
3 Stocks That Are Reshaping the Future
Via InvestorPlace
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
Via MarketBeat
Exposures Product Safety
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Via Talk Markets
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
From Genentech
Via Business Wire
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Via MarketBeat
EXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials
Via Benzinga
Tempest Therapeutics' TPST-1120 Shines In Early Phase 1b/2 Study: Analysts Get Bullish
Via Benzinga
Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost?
Via Investor's Business Daily
Roche's Q1 Highlights: Increased Uptake Of Eye Disease Drug Cushions Sales Decline
Via Benzinga
Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls
Via Investor's Business Daily
EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial
Via Benzinga
New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
From Genentech
Via Business Wire
3 Top Biotech Stocks Defying the Bear Market
Via The Motley Fool
This Company's Non-Invasive Tech Looks To Be Unique In the Market And Can Help People Take Ownership Over Monitoring Their Health
Via Benzinga
Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting
From Genentech
Via Business Wire
Biogen To Report Q1 Earnings: Here's What To Expect
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.